About Us
World-recognized R&D company for creating market value through innovative new drugs

Our history

2023
04
IND approval for TU7710 (bypassing agent for hemophilia)
Phase 1 clinical trial in Korea
03
TU2218 (immuno-oncology drug)
Phase 1b clinical trial in combination with Keytruda initiated
2022
11
TU2218 (immuno-oncology drug) selected for KDDF
(Korea Drug Development Fund) project
08
Out-licensing deal of TU2670 (endometriosis drug)
with Hansoh Pharma for the Chinese market
06
CTCSA (Clinical Trial Collaboration and Supply Agreement)
with MSD for Keytruda and TU2218 (Immuno-oncology drug)
02
CTCSA (Clinical Trial Collaboration and Supply Agreement)
with BeiGene for Tislelizumab and TU2218 (Immuno-oncology drug)
2021
12
MFDS IND approval for TU2218 (Immuno-oncology drug)
Phase 1/2 clinical trial
08
FDA IND approval for TU2218 (Immuno-oncology drug)
Phase 1/2 clinical trial
06
Investment in and strategic partnership with SK plasma
05
Protium Sciences Co., Ltd., a TiumBio company, contract development
and analysis company established
2020
07

EU phase 2 clinical trial initiation for endometrial
treatment (NCE403_TU2670)

New NASH and IPF treatments selected for National
grant for innovative growth of small/medium-sized venture companies in BIG 3 areas
(Ministry of SMEs and Startups)

02
Clinical sample production agreement with
Thermo-Fisher Scientific for Hemophilia
bypassing therapy (TU7710)
2019
11
KOSDAQ IPO (Public offering of 30billion won)
05
Series C funding (40billion won)
02
Technology transfer of endometriosis treatment to
Daewon Pharmaceutical Co., Ltd. (NCE403_TU2670)
2018
12

New drug candidate for lung disease
(NCE401_TU2218)

Technology transfer to Chiesi, a global
pharmaceutical company

09
Selected for a government grant to develop
new hemophilia treatments
(Ministry of SMEs and Startups)
07

Endometriosis treatment (NCE403_TU2670)
EU phase 1b clinical trial CTA approval (Germany)

Selection for government grant for the development
of a new immunization anticancer treatment
(Ministry of Health and Welfare)

05
Series B funding (23.5billion won )
04
Selected as a National grant for the development of
new cancer immunotherapeutic drugs.
(Ministry of Health and Welfare)
2017
05
Series A funding (12billion won )
2016
12
Tiumbio Co. Established